Armistice Capital Master Fund Purchases 137,230 Shares of EyeGate Pharma (EYEG) Stock

EyeGate Pharma (NASDAQ:EYEG) major shareholder Armistice Capital Master Fund acquired 137,230 shares of the company’s stock in a transaction that occurred on Tuesday, May 8th. The shares were acquired at an average price of $0.46 per share, for a total transaction of $63,125.80. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Monday, May 14th, Armistice Capital Master Fund bought 15,758 shares of EyeGate Pharma stock. The stock was purchased at an average price of $0.53 per share, with a total value of $8,351.74.
  • On Friday, May 11th, Armistice Capital Master Fund bought 177,012 shares of EyeGate Pharma stock. The stock was purchased at an average price of $0.51 per share, with a total value of $90,276.12.
  • On Thursday, April 26th, Armistice Capital Master Fund bought 165,522 shares of EyeGate Pharma stock. The stock was purchased at an average price of $0.54 per share, with a total value of $89,381.88.
  • On Friday, April 20th, Armistice Capital Master Fund bought 2,534,478 shares of EyeGate Pharma stock. The stock was purchased at an average price of $0.49 per share, with a total value of $1,241,894.22.
  • On Tuesday, April 17th, Armistice Capital Master Fund bought 10,479,970 shares of EyeGate Pharma stock. The stock was purchased at an average price of $0.36 per share, with a total value of $3,772,789.20.

EyeGate Pharma stock opened at $0.59 on Friday. EyeGate Pharma has a 12-month low of $0.60 and a 12-month high of $0.64.

EyeGate Pharma (NASDAQ:EYEG) last posted its quarterly earnings data on Friday, March 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. EyeGate Pharma had a negative net margin of 2,480.28% and a negative return on equity of 653.57%. equities analysts forecast that EyeGate Pharma will post -0.6 EPS for the current fiscal year.

Several research firms have commented on EYEG. HC Wainwright restated a “buy” rating and issued a $3.00 target price (down previously from $5.00) on shares of EyeGate Pharma in a research report on Tuesday, February 6th. ValuEngine upgraded shares of EyeGate Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

EyeGate Pharma Company Profile

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Insider Buying and Selling by Quarter for EyeGate Pharma (NASDAQ:EYEG)

Receive News & Ratings for EyeGate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyeGate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply